HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia

Fabiana Paladini1*, Francesca Belfiore1,2*, Elisa Cocco1, Carlo Carcassi3, Alberto Cauli4, Alessandra Vacca4, Maria Teresa Fiorillo1, Alessandro Mathieu4, Isabella Cascino2 and Rosa Sorrentino1,5

1Department of Cell Biology and Development, University "La Sapienza", via dei Sardi, 70, 00185 Roma, Italy
2Cell Biology Institute, CNR, via E. Ramarini, 00016 Monterotondo Scalo, Roma, Italy
3Chair of Medical genetics, Department of Internal Medicine, University of Cagliari, SS 554 09042 Monserrato, Cagliari, Italy
4Chair of Rheumatology II, Department of Medical Sciences, University of Cagliari, SS 554 09042 Monserrato, Cagliari, Italy
5Fondazione Pasteur-Cenci Bolognetti, University "La Sapienza", Pz. Aldo Moro 5, 00185 Roma, Italy

* Contributed equally

Corresponding author: Rosa Sorrentino, rosa.sorrentino@uniroma1.it

Received: 7 Aug 2009 Revisions requested: 17 Sep 2009 Revisions received: 24 Sep 2009 Accepted: 13 Nov 2009 Published: 13 Nov 2009

Arthritis Research & Therapy 2009, 11:R171 (doi:10.1186/ar2860)

Abstract

Introduction
Ankylosing spondylitis (AS) is a severe, chronic inflammatory disease strongly associated with HLA-B27. The presence of additional HLA risk factors has been suggested by several studies. The aim of the current study is to assess the occurrence of an additional HLA susceptibility locus in the region between HLA-E and HLA-C in the Sardinian population.

Methods
200 random controls, 120 patients with AS and 175 HLA-B27 positive controls were genotyped for six single nucleotide polymorphisms (SNPs) spanning the HLA region between HLA-E and HLA-C loci previously shown to harbour an additional susceptibility locus for AS. Allele, genotype and haplotype frequencies were compared.

Results
The data confirm our previous finding of a significant increase in patients with AS of allele A at SNP rs1264457 encoding for an Arg at the functional HLA-E polymorphism (Arg128/Gly128). This was due to a remarkable increase in the frequency of genotype A/A in patients vs HLA-B27-matched controls (51% vs 29%; P for trend: 5 × 10⁻⁵). Genotype distribution of three other SNPs mapping in genes (GNL1, PRR3 and ABCF-1) close to HLA-E and showing high LD with it, was also significantly skewed. Accordingly, haplotype distribution was also remarkably different. The frequency of the haplotype AAGA, is 42% in random controls, increases to 53% in the HLA-B27-positive controls, and reaches 68% in patients with AS (P values: 2 × 10⁻¹¹ vs random and 3 × 10⁻⁴ vs HLA-B27 controls).

Conclusions
There is a strong association between the presence of a haplotype in genes mapping between HLA-E and HLA-C and AS due to an increase of homozygous markers in patients. The strongest association however, is with the HLA-E functional polymorphism rs1264457. Since HLA-E is the ligand for the NKG2A receptor, these data point to the natural killer (NK) activity as possible player in the pathogenesis of AS.

Introduction
Ankylosing spondylitis (AS) is a severe, chronic inflammatory disease whose strong association with human leukocyte antigen (HLA)-B27 has been known for many years. However, the presence of HLA-B27 far from accounts for the entire genetic load in AS. Other genes within and outside the HLA region have been evoked as additional factors contributing to the disease [1-4]. Although the association of genes outside the HLA region, such as IL-1, IL23R or endoplasmic reticulum aminopeptidase 1 (ERAP1), has been demonstrated, it appears more difficult to single out independent HLA risk factors, due to the strong Linkage Disequilibrium (LD) among genes map-

ABCF1: ATP-binding cassette, subfamily F (GCN20), member 1; AS: ankylosing spondylitis; ERAP1: endoplasmic reticulum aminopeptidase 1; FOR: Forward; GNL1: guanine nucleotide binding protein-like 1; HLA: human leukocyte antigen; IL: interleukin; NK: natural killer; PCR: polymerase chain reaction; PRR3: proline-rich polypeptide 3; RANP1: member RAS oncogene family pseudogene 1; REV: Reverse; SAP: shrimp alkaline phosphatase; SEQ: Sequencing; SNP: single nucleotide polymorphism.
ping within the HLA region. The Sardinian is an outlier population and, due to the relative low gene flow from outside populations [5], is particularly suitable for case-control association studies in common complex diseases. In previous work, by comparing HLA-B27-positive patients with AS and controls, we have reported that the region between HLA-E and major histocompatibility class I polypeptide-related sequence A (MICA) contains genes showing different allele frequencies between the two cohorts, and that there was an excess of homozygous markers in patients [6]. This allowed us to speculate that the co-occurring chromosome was contributing to the disease providing a double dose of the predisposing allele. Interestingly, among the markers analysed, we found that the functional single nucleotide polymorphism (SNP) in the HLA-E gene (rs1264457A/G; determining the amino acid variation Arg128Gly) showed a significantly different genotype distribution in the two cohorts. Here, we analyse a larger cohort of HLA-B27-positive patients (n = 120) and HLA-B27-positive controls (n = 175) for the distribution of rs1264457 and five other SNPs mapping in genes close to the HLA-E locus. This further analysis confirms the strong association between allele A at rs1264457 in the HLA-E gene and AS.

Materials and methods

In this study, 200 random controls, 120 HLA-B27-positive patients with AS and 175 HLA-B27-matched controls were analysed. Seventy-nine HLA-B27-positive patients and 77 controls (24 of which were typed as B*2709) have been previously described [6]. A further 41 patients with AS and 98 HLA-B27-positive controls (16 of which typed as B*2709) were enrolled in this study. The final subtype distribution was as follows: 108 B*2705 (90%), 6 B*2702 (5%), 4 B*2707 (3%) and 2 B*2713 (2%) in the cohort of patients with AS; and 121 B*2705 (69%), 40 B*2709 (23%), 9 B*2707 (5%) and 5 B*2702 (3%) in the cohort of HLA-B27-positive controls. Population stratification had been controlled by analyzing the distribution of all six SNPs was in Hardy-Weinberg equilibrium. All B*2709 controls were included in the study. Genotype distribution in the two cohorts. Here, we analyse a larger cohort of HLA-B27-positive patients (n = 120) and HLA-B27-positive controls (n = 175) for the distribution of rs1264457 and five other SNPs mapping in genes close to the HLA-E locus. This further analysis confirms the strong association between allele A at rs1264457 in the HLA-E gene and AS.

SNP typing

Five SNPs mapping in the region encompassing about 100 kb between the HLA-E and HLA-C genes have been analysed: rs2105960 in the member RAS oncogene family pseudogene 1 (RANP1) gene, rs1264457 in the HLA-E gene, rs2074505 in the guanine nucleotide binding protein-like 1 (GNL1) gene, rs2074503 in the proline-rich polypeptide 3 (PRR3) gene, and rs2269709 and rs1264439 in the ATP-binding cassette, subfamily F (GCF20), member 1 (ABCF-1) gene. SNPs were typed by minisequencing as previously reported [6]. Briefly, the amplified products were treated with 0.5 U of shrimp alkaline phosphatase (SAP; Roche, Gaillard, France) and 2.5 U of exonuclease I (EXO I; BioLabs, Frankfurt am Main, Germany) at 37°C for 120 minutes and at 50°C for 15 minutes for inactivation. For minisequencing reactions, the commercial fluorescent-based minisequencing kit SNAPshot multiplex (Applied Biosystems, Lincoln Centre Drive, Foster City, USA) was used, with 2 pmoles of primer. PCR for single base extension reaction was as follows: initial denaturation at 94°C for three minutes, followed by 50 cycles of primer extension at 96°C for 15 seconds, annealing at 55 to 59°C (depending on the oligonucleotide annealing temperature) for 15 seconds, extension at 60°C for one minute. After the extension and labelling reaction, the unincorporated dNTPs were removed by enzymatic treatment using 0.5 U of SAP at 37°C for 120 minutes and at 75°C for 15 minutes for inactivation. The products were analyzed on the ABI prism 310 Genetic Analysers (Applied Biosystems, Lincoln Centre Drive, Foster City, USA). Genotyping was performed by 310 ABI Prism GeneScan 2.1 software (Applied Biosystems, Lincoln Centre Drive, Foster City, USA).

Primers were as follows: rs2105960: FOR: AGACGCTCTCTGGAAGGAACA; REV: GGCTGTGTCCATCATATTG; SEQ: ATGGTGATGACTGAAAAACG. rs1264457: FOR: 5'-GTTGGGGGGGGCTGACTAAAG; REV: 5'-GGTCCCTCATTCAGGGTGAAG; SEQ: 5'-TGGCCAGTGCTGGGCGCCGAC. rs2074505: FOR: CACAGGTAGTGGCTTCAGGC; REV: 5'-CCTATAGGAAGCCCTCTGAGAC; SEQ: 5'-GGTGCAGCTGGGGCCCGAC. rs2269709: FOR: GCAAAGAAGCCCTTACAGG; REV: 5'-CCTATAGGAAGCCCTTACAGG; SEQ: 5'-GGTGCAGCTGGGGCCCGAC. rs1264439: FOR: GTCCCGCTCCTTGTAGTCTC; REV: TTAGATGCCCTTGGGGAGG; SEQ: 5'-GGTGCAGCTGGGGCCCGAC. rs1264439: FOR: GCAAAGAAGCCCTTACAGG; REV: 5'-CCTATAGGAAGCCCTTACAGG; SEQ: 5'-GGTGCAGCTGGGGCCCGAC.

PCR

A 20 ng sample of genomic DNA in a volume of 15 μl, containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl₂, 0.2 mM dNTPs, 5 pmol each of forward and reverse primer and 0.75 U of Taq Polymerase (Biotaq DNA Polymerase, Bioline (Bioline Ltd, London, UK) was used. The mixture was incubated at 94°C for three minutes followed by 25 to 30 cycles of denaturation at 94°C for 30 seconds, annealing at a range of 55 to 62°C (depending on the analysed marker) for 30 seconds, extension at 72°C for one minute, with a final step of 72°C for 10 minutes.

Arthritis Research & Therapy Vol 11 No 6 Paladini et al.
Statistical analysis
Two-tailed Fisher’s Exact test was used to assess the differences of proportion of polymorphic alleles and association between random controls and HLA-B27 patients, HLA-B*2705 and HLA-B*2709 controls. The Cochrane-Armitage trend test was performed using StatXact7 software (Massachusetts Ave, Cambridge, USA). P values less than 0.05 were considered significant. LD was calculated using Haplovlew software [10]. Hardy-Weinberg equilibrium testing was performed using Pearson’s goodness-of-fit chi-squared test with one degree of freedom.

Results
We report here allele, genotype and haplotype distribution of six markers spanning the region between HLA-E and HLA-C genes in 175 HLA-B27-positive controls and 120 patients with AS. LD r² values calculated using 200 random controls, are reported in Figure 1. Marker rs2105960 mapping in the pseudogene RANP1 shows no LD with the others. A central block of LD is evident going from HLA-E rs1264457 to rs2269709 in the ABCF1 gene. Allele frequencies of these six SNPs in HLA-B27-positive patients with AS and controls is reported in Table 1. RANP1 rs 2105960, mapping upstream HLA-E and not in LD with it, shows a similar allele frequency in patients with AS and HLA-B27 controls. According to our previous data [6], HLA-E rs1264457 shows the highest association with AS (P = 1 × 10⁻⁴; odds ratio = 2; 95% confidence interval = 1.4 to 2.9). In parallel with the decrease of the LD, the strength of association of the other markers mapping downstream the HLA-E gene, also decreases. Rs1264439, mapping in the ABCF1 gene, is almost monomorphic and shows no association. As expected, genotype distribution of the HLA-E rs1264457 is significantly different between patients with AS and HLA-B27-positive controls (P-trend = 5 × 10⁻⁵) with a strong increase in genotype AA in patients (51% vs 29%). Genotype AG is present in 60% of B27 controls vs 46% of patients with AS. The other markers in high LD with it, also show significant P-trend values which, however, downgrade the more the distance from rs1264457. As expected, haplotype distribution of the four SNPs showing association, rs1264457/rs2074505/rs2074503/rs2269709, is also different between patients and controls (Table 2). HLA-E rs1264457 allele A is a marker of the HLA-B27 haplotype in Sardinia. Accordingly, the haplotype AAGA is significantly over-represented among the HLA-B27-positive controls (53% calculated using the overall cohort of the HLA-B27 controls compared with 42% in random controls, P value = 9 × 10⁻⁴). Haplotype distribution in the HLA-B*2709-positive cohort is reported in Table 2. Although the number of subjects analysed is low (n = 40), it is evident that the distribution is, if any, more similar to that of the AS patients than to the HLA-B27 controls indicating that the same AAGA haplotype is a feature of both the B*2705- and the B*2709-positive cohorts. For this reason, the statistical analysis has always been performed pooling all B27 controls in one single cohort. Due to the homozygous status of the corresponding markers, patients with AS show an even higher frequency of the 'B27 haplotype' (AAGA: 68%). The other frequent haplotype, GGAG, is under-represented in patients compared with the HLA-B27 controls, in which the increase of the haplotype AAGA is counterbalanced by a proportional lower frequency of all the other haplotypes.

Discussion
The data reported here validate our previous observation of a strong association between a functional polymorphism of the HLA-E gene and AS in Sardinia. It has been shown that the signal peptide of the HLA-B27 molecules binds with low affinity to the HLA-E Arg128 variant [11] and therefore the absence of the alternative variant, Gly128 in patients, could result in a reduced expression of the HLA-E molecules on the cell surface. This, in turn, could lead to an imbalance of the inhibitory function of HLA-E on natural killer (NK) activity or to an alteration of regulatory functions as it has been shown in animal models of autoimmune diseases [12]. More and more reports are involving the HLA-E-NKG2A pathway in autoimmune/inflammatory diseases. Recently, a polymorphism mapping in the HLA-E gene has been found to be associated with
Table 1

Allele frequencies and Cochrane-Armitage test for trend of genotype distribution in patients with AS and HLA-B27-matched controls in Sardinia

| Gene  | SNP          | Position on chromosome 6 | HLA-B27+ controls n = 175 | HLA-B27+ patients with AS n = 120 |
|-------|--------------|---------------------------|---------------------------|-----------------------------------|
|       | MAF (%)      | MAF (%)                   | P                  | OR (95% CI)                       |
| RANP1 | rs2105960    | 30561768                  | 245 (75)             | 154 (69)                          |
|       |              |                           | ns                  |                                   |
|       | TT           | 94 (57)                   | 49 (44)              |                                   |
|       | CT           | 63 (38)                   | 56 (50)              |                                   |
|       | CC           | 9 (5)                     | 7 (6)                |                                   |
|       | P trend      |                           | ns                  |                                   |
| HLA-E | rs1264457    | 30566040                  | 207 (59)             | 177 (74)                          |
|       |              |                           | 1 × 10^-4            | 2.14 (1.9-2.9)                    |
|       | AA           | 51 (29)                   | 61 (51)              | Ref                               |
|       | AG           | 105 (60)                  | 55 (46)              | 1 × 10^-3 0.44 (0.27-0.72)        |
|       | GG           | 19 (11)                   | 3 (3)                | 4 × 10^-4 0.13 (0.04-0.5)         |
|       | P trend      |                           | 5 × 10^-5            |                                   |
| GNL1  | rs2074505    | 30629116                  | 219 (63)             | 179 (76)                          |
|       |              |                           | 4 × 10^-4            | 1.9 1.4-2.8                       |
|       | AA           | 68 (39)                   | 68 (58)              | Ref                               |
|       | AG           | 83 (47)                   | 43 (37)              | 0.01 0.52 (0.31-0.85)             |
|       | GG           | 24 (14)                   | 6 (5)                | 4 × 10^-3 0.25 (0.1-0.65)         |
|       | P trend      |                           | 4 × 10^-4            |                                   |
| PRR3  | rs2074503    | 30638475                  | 247 (76)             | 203 (85)                          |
|       |              |                           | 9 × 10^-3            | 1.8 1.2-2.7                       |
|       | GG           | 93 (57)                   | 85 (71)              | Ref                               |
|       | AG           | 61 (37)                   | 33 (28)              | 0.05 0.59 (0.35-1)                |
|       | AA           | 10 (6)                    | 2 (1)                | 0.04 0.22 (0.05-1)                |
|       | P trend      |                           | 7 × 10^-3            |                                   |
| ABCF1 | rs2269709    | 30648869                  | 224 (74)             | 201 (84)                          |
|       |              |                           | 5 × 10^-3            | 1.8 1.2-2.8                       |
|       | AA           | 82 (54)                   | 83 (69)              | Ref                               |
|       | AG           | 60 (39)                   | 35 (29)              | 0.04 0.58 (0.34-0.99)             |
|       | GG           | 10 (7)                    | 2 (2)                | 0.03 0.2 0.04 (0.04-0.9)          |
|       | P trend      |                           | 4 × 10^-3            |                                   |
| ABCF1 | rs1264439    | 30660481                  | 312 (91)             | 212 (91)                          |
|       |              |                           | ns                  |                                   |
|       | GG           | 142 (83)                  | 97 (84)              |                                   |
|       | GT           | 28 (16)                   | 18 (15)              |                                   |
|       | TT           | 1 (1)                     | 1 (1)                |                                   |
|       | P trend      |                           | ns                  |                                   |

AS = ankylosing spondylitis; CI = confidence interval; MAF = major allele frequency; ns = not significant; OR = odds ratio; SNP = single nucleotide polymorphism.
Kawasaki disease [13] and the HLA-E-NKG2A pathway is likely to play a role in celiac disease [14]. From the data reported here, it seems unlikely that a HLA-E neighboring gene rather than HLA-E itself, could be the real factor contributing to the disease. The data reported here strongly suggest that NK activity could be involved in the pathogenesis of AS [15] although the HLA-E molecules themselves are not necessarily responsible for this in all populations. As an example, two studies performed in a Spanish and an Asian population reports an imbalance of KIR alleles between patients with AS and HLA-B27-matched controls but these data have not been replicated in a further study in an English cohort [16-18]. This might indicate that different pathways have been selected in different populations based on their genetic background and environmental pressure, leading to the impairment of a crucial function, which can be imbalanced towards an exceeding effector or a defective regulatory function. If this is the case, the more promiscuous the population is, the more difficult it can be to identify some of the minor predisposing genes. For this reason, isolated populations which have undergone strong selection by environmental factors as it occurred in Sardinia, might be particularly informative to single out genes that predispose to complex diseases particularly in those cases in which a gene with a strong effect, such as HLA-B27, plays a leading role [19].

Conclusions

There is a strong association between a gene mapping in the region between HLA-E and HLA-C and AS in Sardinia. This gene is most likely to be the HLA-E itself because the functional polymorphism rs1264457 encoding for an Arg at position 128 found to be functionally relevant shows the strongest association.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

FP, FB and EC have performed DNA extraction, genotyping and statistical analysis. AC, AV and AM have contributed to the recruitment, analysis and diagnosis of the patients. CC has contributed his collection of HLA-B27-positive controls and their HLA-typing in Sardinia. MTF, IC, CC, AM and RS have contributed to the disease analysis of HLA-B27 extended haplotypes in Sardinia. This work was partially supported by Fondazione Pasteur-Cenci Bolognetti.

Acknowledgements

The authors wish to thank the patients for their cooperation, and Federica Lucantoni and Silvana Caristi for their excellent technical assistance.

References

1. Wellcome Trust Case Control Consortium; Australo-Anglo-Ameri- can Spondylitis Consortium (TASC): Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337.
2. Zhu X, Wang Y, Sun L, Song Y, Sun F, Tang L, Huo Z, Li J, Yang Z: A novel gene variation of TNFalpha associated with ankylos- ing spondylitis: a reconfirmed study. Ann Rheum Dis 2007, 66:1419-1422.
3. Brown MA: Genetics and the pathogenesis of ankylosing spondylitis. Curr Opin Rheumatol 2009, 21:318-323.
4. Sims AM, Barnardo M, Herzberg I, Bradbury L, Calin A, Words- worth BP, Darce C, Brown MA: Non-B27 MHC associations of ankylosing spondylitis. Genes Immun 2007, 8:115-123.
5. Contu D, Morelli L, Santoni F, Foster JW, Francalacci P, Cucca F: Y-chromosome based evidence for pre-neolithic origin of the genetically homogeneous but diverse Sardinian population: inference for association scans. PloS One 2008, 30:e1430.
6. Cascino I, Paladini F, Belfiore F, Cauli A, Angelini C, Fiorillo MT, Mathieu A, Sorrentino R: Identification of previously unrecog- nized predisposing factors for ankylosing spondylitis from analysis of HLA-B27 extended haplotypes in Sardinia. Arthritis Rheum 2007, 56:2640-2651.
7. Paladini F, Cocco E, Cauili A, Cascino I, Vacca A, Belfiore F, Fiorillo MT, Mathieu A, Sorrentino R: A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B'2705 in Sardinia. Genes Immun 2008, 9:659-667.
8. D’Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zuccarelli A, Bitti PP, Tosi R, Sorrentino R: Relevance of residue 116 of HLA-B27

Table 2

| Haplotypes | Random controls | HLA-B27 controls | P   | HLA-B27 patients with AS | p1     | p2     |
|------------|----------------|-----------------|-----|--------------------------|--------|--------|
| rs1264457/rS2074505/rs2074503/rs2269709 | 0.52 (0.59)* | 9 × 10⁻⁴   | 0.68 | 2 × 10⁻¹¹  | 3 × 10⁻⁴ |
| AAGA       | 0.42           | 0.23 (0.16)   | ns  | 0.12                     | 1 × 10⁻⁴ | 0.001  |
| GGAG       | 0.24           | 0.10 (0.10)   | ns  | 0.05                     | 7 × 10⁻⁴ | ns     |
| GGGA       | 0.14           | 0.15 (0.15)   | ns  | 0.15                     | ns     | ns     |

in brackets = haplotype frequencies referring to 40 HLA-B27 positive subjects which had been enclosed in the statistical analysis; p1 = HLA-B27 positive patients with AS vs random controls; p2 = HLA-B27 positive patients with AS vs the pool of the HLA-B27 positive controls. AS = ankylosing spondylitis.

Available online http://arthritis-research.com/content/11/6/R171
in determining susceptibility to ankylosing spondylitis. *Eur J Immunol* 1995, 25:3199-3201.

9. Linden SM Van der, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. *Arthritis Rheum* 1984, 27:361-368.

10. Haploview software [http://www.broad.mit.edu/mpg/haploview/](http://www.broad.mit.edu/mpg/haploview/).

11. Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty E: HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. *J Biol Chem* 2003, 278:5082-5090.

12. Lu L, Kim HJ, Wernette MB, Cantor H: Regulation of CD8+ regulatory T cells: Interruption of the NKG2A-Qa-1 interaction allows robust suppressive activity and resolution of autoimmune disease. *Proc Natl Acad Sci USA* 2008, 105:19420-19425.

13. Lin YJ, Wan L, Wu JY, Sheu JJ, Lin CW, Lan YC, Lai CH, Hung CH, Tsai Y, Tsai CH, Lin TH, Lin JG, Hsueh KC, Huang YM, Chang JS, Tsai FJ: HLA-E gene polymorphism associated with susceptibility to Kawasaki disease and formation of coronary artery aneurysms. *Arthritis Rheum* 2008, 60:804-810.

14. Bhagat G, Nayer AJ, Shah JG, Harper J, Jabri B, Wang TC, Green PH, Manavalan JS: Small intestinal CD8+TCRgam-delta+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. *J Clin Invest* 2008, 118:281-293.

15. Kollmerberger S, Chan A, Sun MY, Chen LY, Wright C, di Gleria K, McMichael A, Bowness P: Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. *Eur J Immunol* 2007, 37:1313-1322.

16. Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC, Bruges Armas J, Suarez-Alvarez B, Pruneda L, Couto AR, Gonzalez S, Lopez-Vazquez A, Martinez-Borra J: Contribution of KIR3DL1/3DL1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. *Arthritis Res Ther* 2008, 10:R101.

17. Diaz-Peña R, Blanco-Gelaz MA, Suarez-Alvarez B, Martinez-Borra J, Lopez-Vazquez A, Alonso-Arias R, Brügues-Armas J, Vidal-Castiñeira JR, Lopez-Larrea C: Activating KIR genes are associated with ankylosing spondylitis in Asian populations. *Hum Immunol* 2008, 69:437-442.

18. Harvey D, Pointon JJ, Sleator C, Meenagh A, Farrar C, Sun JY, Senitzer D, Middleton D, Brown MA, Wordsworth BP: Analysis of killer immunoglobulin-like receptor genes in ankylosing spondylitis. *Ann Rheum Dis* 2009, 68:595-598.

19. Mathieu A, Paladini F, Vaccia A, Cauli A, Fiorillo MT, Sorrentino R: The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. *Autoimmun Rev* 2009, 8:420-425.